Condition: Systemic Sclerosis Associated Interstitial Lung Disease · Scleroderma, Systemic · Sponsor: GlaxoSmithKline
This study investigates the efficacy and safety of belimumab compared to placebo, in addition to standard therapy, for the treatment of participants with systemic sclerosis associated interstitial lung disease (SSc-ILD). The study will evaluate the effect of belimumab treatment on lung function as well as on extra-pulmonary disease manifestations, including skin thickening and general symptoms, such as fatigue, that impact quality of life (QoL).
This description comes directly from the study's public registry record.
US GSK Clinical Trials Call Center · 877-379-3718 · GSKClinicalSupportHD@gsk.com
EU GSK Clinical Trials Call Center · +44 (0) 20 89904466 · GSKClinicalSupportHD@gsk.com
Always discuss trial participation with your own doctor first.
| GSK Investigational Site | Phoenix, Arizona, United States | Completed |
| GSK Investigational Site | Scottsdale, Arizona, United States | Recruiting |
| GSK Investigational Site | Scottsdale, Arizona, United States | Recruiting |
| GSK Investigational Site | Tucson, Arizona, United States | Recruiting |
| GSK Investigational Site | Los Angeles, California, United States | Recruiting |
| GSK Investigational Site | Los Angeles, California, United States | Recruiting |
| GSK Investigational Site | Los Angeles, California, United States | Recruiting |
| GSK Investigational Site | Upland, California, United States | Recruiting |
| GSK Investigational Site | Aurora, Colorado, United States | Recruiting |
| GSK Investigational Site | Washington D.C., District of Columbia, United States | Recruiting |
| GSK Investigational Site | Jacksonville, Florida, United States | Recruiting |
| GSK Investigational Site | Miami, Florida, United States | Recruiting |
+ 119 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05878717